You are here

Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab

Significant milestone toward the commercialization of eptinezumab, the first quarterly infusion therapy for migraine prevention Significant milestone toward the commercialization of eptinezumab, the first quarterly infusion therapy for migraine prevention
Friday, February 22, 2019 - 08:00